asco

News

ASCO: AffyImmune claims a first with CAR-T for solid tumours

AffyImmune Therapeutics has recorded what it says is the first documented complete response in a patient with a solid tumour treated with CAR-T therapy.

News

ASCO: Merus bispecific garners attention after abstract drop

Among the myriad of new studies highlighted in the newly published ASCO abstracts, Merus’ seems to have struck a chord with its phase 2 trial of bispecific antibody petosemtamab in he

News

Trial data raises questions about Imfinzi in liver cancer

AstraZeneca is trying to blaze a new trial for immunotherapy in liver cancer with its EMERALD-1 trial, but the jury is out on its prospects.

News

BMS eyes first-line colorectal cancer use for Opdivo-Yervoy

The combination of Bristol-Myers Squibb’s Opdivo and Yervoy cancer immunotherapies is on track for approval as a first-line therapy for patients with a particular form of

Oncology

Oncology 2023

Oncology 2023 features interviews, analysis, and commentary from pharmaphorum, industry leaders, and more

News

J&J files Carvykti for earlier use in multiple myeloma

As the ASCO congress drew to a close, Johnson & Johnson filed for FDA approval of its BCMA-targeting CAR-T therapy Carvykti for use earlier in the treatment pathway fo

ASCO: AffyImmune claims a first with CAR-T for solid tumours

ASCO: Merus bispecific garners attention after abstract drop

Trial data raises questions about Imfinzi in liver cancer

BMS eyes first-line colorectal cancer use for Opdivo-Yervoy

Oncology 2023

J&J files Carvykti for earlier use in multiple myeloma

NHS use of digital cardiac rehab tools endorsed

How to meet your physicians where they are online

asco

Editor's Picks